The impact of neoadjuvant chemotherapy (NACT) on the tumor immune microenvironment (TME) in patients with colorectal cancer with liver metastases (CRCLM).

Abstract

124 Background: Microsatellite stable (MSS) colorectal cancer and CRCLM are highly resistant to current immunotherapeutic approaches. Understanding the TME and the impact of standard chemotherapeutics is of utmost importance in developing optimal therapeutic strategies. Data is limited on the impact of NACT in the TME. In this study, we sought to explore the effects of chemotherapy on the proportions of different immune cell populations [Total leukohematopoetic cells, CD45+, T cell markers, CD3+, CD8+, and macrophage (M) markers, CD163+, CD68+)], as well as to assess their prognostic capacity. Methods: CRCLM pts who underwent liver resection were divided in 2 groups: pts who had NACT within 4 months of liver resection [NACT (+)] and no NACT [NACT (-)]. Whole slide staining of metastatectomy specimen for CD3, CD8, CD68, CD163, and CD45 was done. Cellular density within representative tumor core sections was analyzed. Retrospective chart review was done to obtain clinical data. Disease free (DFS), relapse free (RFS), and overall survival (OS) were analyzed using Kaplan Meir methods. Association between markers and outcomes was evaluated using Cox Regression Models. Results: A total of 43 pts were studied [NACT (+), n= 14; NACT (-), n=29). There were no significant differences in baseline characteristics between the two groups, including age, primary site, T stage, N stage, and grade. Median OS was 48 months. Outcomes were not significantly different with use of NACT. Within the NACT (+) CRCLM significant increases were seen in densities of CD3, CD8, CD45 and CD163 cells. Densities of CD8 cells were strongly correlated to CD163 cell densities ([r] 0.77, p < .0001). The NACT (+) cohort saw significantly increased ratios of T-cells/macrophages as compared to NACT (-) (CD3/CD68, CD3/CD163, CD8/CD163). High CD45 density was associated with improved OS (HR = 0.28, p = 0.006). CD3, CD8, CD68, and CD163 were not independently associated with OS. However, both the ratio of CD3/CD68 and CD3/163 were associated with improved OS (HR 0.44, p=0.03 and HR 0.27, p=0.03 respectively). Conversely, CD68/45 and CD163/CD45 ratios were associated with a worse OS (HR 1.42, p=0.05 and HR 1.43, p=0.03 respectively). No difference was seen in cellular populations based on the type of NACT received: oxaliplatin vs irinotecan. Conclusions: Our study highlights that the administration of NACT is associated with favorable changes in LM TME. While there is a general increase in leukocytes (CD45), the density of CD3+ and CD8+ T cells is particularly increased. Further, this increase is proportionately greater than the concurrent increases on monocytoid populations, reflected by increased CD3/CD163 and CD8/CD163 ratios. Ratios of T-cells/ macrophages are predictive of survival. This study was partly supported by the American Cancer Society Grant, 126771-IRG-14-194-11-IRG.